Paper · 41612972
Muribaculum intestinale negatively impacts glioma growth in mice through the toll-like receptor 2.
Marrocco F and 18 others. Gut Microbes, 2026. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Muribaculum intestinale negatively impacts glioma growth in mice through the toll-like receptor 2. Papers, record 41612972. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41612972
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Muribaculum intestinale negatively impacts glioma growth in mice through the toll-like receptor 2.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Toll-Like Receptor 2 | Major topic |
| Glioma | Major topic |
| Brain Neoplasms | Major topic |
| Animals | |
| Mice | |
| Feces | |
| Gastrointestinal Microbiome | |
| Mice, Inbred C57BL | |
| CD8-Positive T-Lymphocytes | |
| Tumor Necrosis Factor-alpha | |
| Humans | |
| Microglia | |
| Male |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19,617,889 | Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. | Nat Protoc | 2009 | https://conductscience.org/library/papers/19617889 | PubMed |
| 2 | 31,094,420 | CD1d Modulates Colonic Inflammation in NOD2-/- Mice by Altering the Intestinal Microbial Composition Comprising Acetatifactor muris. | J Crohns Colitis | 2019 | https://conductscience.org/library/papers/31094420 | PubMed |
| 3 | 34,492,236 | Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan. | Pharmacol Ther | 2022 | https://conductscience.org/library/papers/34492236 | PubMed |
| 4 | 22,659,832 | Acetatifactor muris gen. nov., sp. nov., a novel bacterium isolated from the intestine of an obese mouse. | Arch Microbiol | 2012 | https://conductscience.org/library/papers/22659832 | PubMed |
| 5 | 39,147,758 | Astrocytes and the tumor microenvironment inflammatory state dictate the killing of glioblastoma cells by Smac mimetic compounds. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/39147758 | PubMed |
| 6 | 37,224,228 | Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma. | Sci Transl Med | 2023 | https://conductscience.org/library/papers/37224228 | PubMed |
| 7 | 28,198,370 | Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. | Nat Commun | 2017 | https://conductscience.org/library/papers/28198370 | PubMed |
| 8 | 21,512,004 | The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. | Science | 2011 | https://conductscience.org/library/papers/21512004 | PubMed |
| 9 | 39,255,678 | Quantitative analysis of immune cells within the tumor microenvironment of glioblastoma and their relevance for prognosis. | Int Immunopharmacol | 2024 | https://conductscience.org/library/papers/39255678 | PubMed |
| 10 | 37,871,232 | A Cardiolipin from Muribaculum intestinale Induces Antigen-Specific Cytokine Responses. | J Am Chem Soc | 2023 | https://conductscience.org/library/papers/37871232 | PubMed |
1 to 10 of 59
See all 59 referencesCited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,824,216 | 3-hydroxy-3-methylbutyrate (3H3MB) suppresses glioma growth and extends survival in mice. | Front Mol Neurosci | 2026 | https://conductscience.org/library/papers/42824216 | PubMed |
| 42,602,314 | Correlative study of Parnassia palustris extract on orthotopic glioma suppression and gut microbiota modulation in mice. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42602314 | PubMed |
| 42,198,987 | Myco-foods and the gut microbiome: impacts of mycelial extracts, biomass, and mold-fermented foods. | Gut Microbes | 2026 | https://conductscience.org/library/papers/42198987 | PubMed |
| 42,153,622 | Oral Lactobacillus reuteri Combined With Intravenous Lysis-Circuit-Bearing Engineered Bacteria RE Enhances Antitumor Efficacy. | Biotechnol J | 2026 | https://conductscience.org/library/papers/42153622 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data2
The data bank entries PubMed's record names. Trial numbers are under Trials.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41612972
GET https://conductscience.org/api/papers/v1/41612972/references?page=2